{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:27:55Z","timestamp":1785493675256,"version":"3.56.0"},"reference-count":32,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Background: Semaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM) and weight management. While its clinical benefits are well established, concerns have emerged over off-label use, underreporting of adverse drug reactions (ADRs), and prescribing disparities. Aims: To examine real-world prescribing pattern treatment efficacy and ADRs associated with semaglutide in a socioeconomically deprived United Kingdom (UK) locality, and to compare these with national data. Methods: A retrospective service evaluation was conducted using anonymised data from 1403 patients across 42 GP practices under a data share agreement across a place-based group of practices in the West Midlands. National prescribing data were obtained from OpenPrescribing, and ADR data from the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme (01\/2020\u201312\/2024). Analyses included demographic trends, treatment efficacy (HbA1c and weight), and socioeconomic comparisons using the Socioeconomic Index for Small Areas (SEISA) deciles. Findings: Semaglutide prescribing in the GP surgeries studied peaked in 2022 and declined thereafter, mirroring national trends. Prescribing of semaglutide mirrored the ethnic make-up of the region studied with a notable exception of White British. Mean HbA1c fell by 10.8 mmol\/mol and weight by 4.8%. ADR incidence in the population studied (1.85%) exceeded national reporting rates (0.20%). Prescribing was highest in practices serving the most deprived communities. Conclusions: Semaglutide is effective in reducing HbA1c and weight in real-world settings. However, ADRs remain underreported. Socioeconomic deprivation was strongly associated with higher prescribing rates. Greater attention to equitable access and pharmacovigilance is warranted.<\/jats:p>","DOI":"10.3390\/healthcare14010035","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:05:22Z","timestamp":1766498722000},"page":"35","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation"],"prefix":"10.3390","volume":"14","author":[{"given":"Abigail","family":"Whorton","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0723-1290","authenticated-orcid":false,"given":"Samira","family":"Osman","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspal","family":"Johal","sequence":"additional","affiliation":[{"name":"The Dudley Group NHS Foundation Trust, Pensnett Road, Dudley DY1 2HQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-5216","authenticated-orcid":false,"given":"Sarah","family":"Baig","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-5626","authenticated-orcid":false,"given":"Alan M.","family":"Jones","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6126-3379","authenticated-orcid":false,"given":"Zahraa","family":"Jalal","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Yi, Z. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721135"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jcpt.13230","article-title":"A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents","volume":"45","author":"Cornell","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_3","unstructured":"National Institute for Health and Care Excellence (2024, October 26). Clinical Knowledge Summaries (CKS): Diabetes\u2013Type 2: GLP-1 Receptor Agonists. Available online: https:\/\/cks.nice.org.uk\/topics\/diabetes-type-2\/prescribing-information\/glp-1-receptor-agonists\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/8755122518790925","article-title":"Semaglutide for the Treatment of Type 2 Diabetes Mellitus","volume":"34","author":"Miles","year":"2018","journal-title":"J. Pharm. Technol."},{"key":"ref_5","unstructured":"Electronic Medicines Compendium (2024, November 03). Ozempic 0.25 mg Solution for Injection in Pre-Filled Pen. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/9748\/smpc."},{"key":"ref_6","unstructured":"Electronic Medicines Compendium (2024, November 03). Wegovy 0.25 mg, FlexTouch Solution for Injection in Pe-Filled Pen. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/13799\/smpc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double blind, randomized, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","unstructured":"Diabetes UK (2024, November 03). Our Response to Serious Supply Issues of Drugs for People with Type 2 Diabetes. Available online: https:\/\/www.diabetes.org.uk\/about-us\/news-and-views\/our-response-serious-supply-issues-drugs-people-living-type-2-diabetes."},{"key":"ref_10","unstructured":"BBC News (2024, December 22). Weight Loss Injection Hype Fuels Online Black Market. Available online: https:\/\/www.bbc.co.uk\/news\/health-67414203."},{"key":"ref_11","unstructured":"The Pharmaceutical Journal (2024, November 03). The Unregulated Semaglutide Prescribing Circus. Available online: https:\/\/pharmaceutical-journal.com\/article\/opinion\/the-unregulated-semaglutide-prescribing-circus."},{"key":"ref_12","unstructured":"Gov.UK (2025, January 01). MHRA Warns of Unsafe Fake Weight Loss Pens, Available online: https:\/\/www.gov.uk\/government\/news\/mhra-warns-of-unsafe-fake-weight-loss-pens."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Smits, M.M., and Van Raalte, D.H. (2021). Safety of Semaglutide. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.645563"},{"key":"ref_14","unstructured":"Gov.UK (2024, November 03). MHRA Reminds Healthcare Professionals to Advise Patients of the Side Effects of GLP-1 Agonists and to Report Misuse, Available online: https:\/\/www.gov.uk\/government\/news\/mhra-reminds-healthcare-professionals-to-advise-patients-of-the-side-effects-of-glp-1-agonists-and-to-report-misuse."},{"key":"ref_15","unstructured":"National Institute for Health and Care Excellence (2024, November 03). British National Formulary: Semaglutide\u2013Side-effects. Available online: https:\/\/bnf.nice.org.uk\/drugs\/semaglutide\/#side-effects."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu, L., Liu, Y., Li, C., Zhang, Y., Liu, M., and Wu, X. (2024). Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviours: A pharmacovigilance study based on the FDA Adverse Event Reporting System database. BMC Med., 22.","DOI":"10.1186\/s12916-024-03274-6"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-024-04112-8","article-title":"Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: A pharmacovigilance study based on the FDA adverse event reporting system database","volume":"88","author":"Zhou","year":"2024","journal-title":"Endocrine"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., and Zhang, Q. (2022). Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.996179"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Butuca, A., Dobrea, C.M., Arseniu, A.M., Frum, A., Chis, A.A., Rus, L.L., Ghibu, S., Juncan, A.M., Muntean, A.C., and Laz\u0103r, A.E. (2024). An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database. Biomedicines, 12.","DOI":"10.20944\/preprints202404.1954.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e15748863367086","DOI":"10.2174\/0115748863367086250420011411","article-title":"A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists","volume":"20","author":"Amirthalingam","year":"2025","journal-title":"Curr. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41591-023-02669-x","article-title":"Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity","volume":"30","author":"Waldrop","year":"2024","journal-title":"Nat. Med."},{"key":"ref_22","unstructured":"NHS Black Country Integrated Care Board (2024, December 28). Our Five Year Joint Forward Plan. Available online: https:\/\/blackcountry.icb.nhs.uk\/about-us\/our-priorities\/our-5-year-joint-forward-plan."},{"key":"ref_23","unstructured":"(2024, October 24). Semaglutide (0601023AW). Available online: https:\/\/openprescribing.net\/chemical\/0601023AW\/."},{"key":"ref_24","unstructured":"Medicines & Healthcare Products Regulatory Agency (2024, October 24). Yellow Card: Interactive Drug Analysis Profile, Available online: https:\/\/info.mhra.gov.uk\/drug-analysis-profiles\/dap.html?drug=.\/UK_EXTERNAL\/NONCOMBINED\/UK_NON_000329053901.zip&agency=MHRA."},{"key":"ref_25","unstructured":"Higher Education Statistics Agency (2024, October 24). Socioeconomic Index for Small Areas (SEISA)\u2013England Map. Available online: https:\/\/www.hesa.ac.uk\/data-and-analysis."},{"key":"ref_26","unstructured":"Gov.UK (2024, November 21). Yellow Card: Please Help to Reverse the Decline in Reporting of Suspected Adverse Drug Reactions, Available online: https:\/\/www.gov.uk\/drug-safety-update\/yellow-card-please-help-to-reverse-the-decline-in-reporting-of-suspected-adverse-drug-reactions."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/01410768231198442","article-title":"Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"117","author":"Kunutsor","year":"2024","journal-title":"J. R. Soc. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1210\/clinem\/dgz072","article-title":"Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials","volume":"105","author":"DeSouza","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","unstructured":"The Pharmaceutical Journal (2025, January 01). Pharmacy Regulator to Require \u2018Two-Way Communication\u2019 in New Draft Guidance. Available online: https:\/\/pharmaceutical-journal.com\/article\/news\/pharmacy-regulator-to-require-two-way-communication-in-new-draft-guidance."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ije\/dyr029","article-title":"Type 2 diabetes incidence and socio-economic position: A systematic review and meta-analysis","volume":"40","author":"Agardh","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/pdi.2435","article-title":"Health inequalities and diabetes","volume":"40","author":"Kilvert","year":"2023","journal-title":"Pract. Diabetes"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/1\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:31:32Z","timestamp":1766500292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/1\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["healthcare14010035"],"URL":"https:\/\/doi.org\/10.3390\/healthcare14010035","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}